Internal Medicine, Cardiovascular Disease · Ocala, FL
NPI
1578548970
Since 2005
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2111 SW 20th Pl
Ocala, FL, 34471
Phone (352) 622-4251
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
17,950 services
Medicare patients, 2024
2,902
Average age 77
Drug cost, 2024
$3.8M
17,102 prescriptions
Company payments, 2025
$1,203
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Srisha Rao was code 99214 (office e&m - established), 2,560 times for 1,595 patients. In total Srisha Rao billed 17,950 services in 53 codes, and Medicare paid $2.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-03-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 2,560 | 1,595 | $93.99 | $241K |
| 99213 Office E&M - Established | Office | 1,890 | 1,574 | $66.51 | $126K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 1,820 | 455 | $5.53 | $10K |
| 93306 Echocardiography (TTE/TEE) | Office | 1,211 | 1,195 | $143.77 | $174K |
| 93296 External Electrocardiographic Monitoring | Office | 928 | 286 | $15.86 | $15K |
| A9555 Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 892 | 446 | $338.13 | $302K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 724 | 676 | $13.83 | $10K |
| 93294 External Electrocardiographic Monitoring | Office | 704 | 219 | $22.51 | $16K |
| 93297 External Electrocardiographic Monitoring | Office | 570 | 96 | $46.82 | $27K |
| 93015 Electrocardiogram | Office | 481 | 480 | $58.42 | $28K |
| 93793 Care Management/Coordination | Office | 470 | 43 | $8.32 | $3,910 |
| 85610 Clinical Chemistry | Office | 459 | 45 | $4.20 | $1,928 |
| 78431 Myocardial Perfusion Scan | Office | 446 | 446 | $1,885.53 | $841K |
| 78434 Myocardial Perfusion Scan | Office | 443 | 443 | $454.02 | $201K |
| 93298 External Electrocardiographic Monitoring | Office | 324 | 41 | $79.75 | $26K |
By year: 2022 $1.8M for 14,718 services; 2023 $1.9M for 15,177 services; 2024 $2.2M for 17,950 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 459 | 45 | $4.20 | $1,928 |
Medicare prescription drug claims, 2024
In 2024, the drug Srisha Rao prescribed most often to Medicare patients was Metoprolol Succinate, with 2,082 prescriptions and refills. In total Srisha Rao wrote 17,102 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Metoprolol Succinate Generic | 2,082 | 6,082 | 710 | $32K |
| Eliquis Apixaban | 1,395 | 3,103 | 394 | $1.8M |
| Atorvastatin Calcium Generic | 1,006 | 2,983 | 339 | $9,156 |
| Losartan Potassium Generic | 940 | 2,762 | 328 | $9,349 |
| Amlodipine Besylate Generic | 933 | 2,741 | 323 | $6,426 |
| Rosuvastatin Calcium Generic | 870 | 2,568 | 286 | $11K |
| Lisinopril Generic | 548 | 1,616 | 189 | $4,167 |
| Furosemide Generic | 521 | 1,465 | 210 | $3,346 |
| Metoprolol Tartrate Generic | 504 | 1,465 | 174 | $3,893 |
| Carvedilol Generic | 495 | 1,427 | 166 | $5,295 |
| Clopidogrel Clopidogrel Bisulfate | 426 | 1,247 | 165 | $5,011 |
| Entresto Sacubitril/Valsartan | 409 | 914 | 124 | $580K |
| Xarelto Rivaroxaban | 369 | 914 | 106 | $492K |
| Potassium Chloride Generic | 355 | 1,008 | 147 | $7,413 |
| Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide | 326 | 962 | 123 | $5,149 |
Brand drugs: 2,966 claims; generic drugs: 14,136 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Srisha Rao $1,203 ($1,203 in general payments such as food, travel and fees) from 13 companies. The largest payer was Pfizer Inc. with $287.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 14 | $287 |
| CVRx, Inc. CVRX | 2 | $269 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $115 |
| Amgen Inc. AMGN | 5 | $97 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 1 | $95.63 |
| Alnylam Pharmaceuticals Inc. ALNY | 3 | $80.51 |
| Kestra Medical Technology Services, Inc. | 2 | $76.22 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $66.92 |
| Boston Scientific Corporation BSX | 1 | $34.38 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $27.23 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.